
may pm et
summari lead global supplier health care product well world largest
manufactur privat label over-the-counter pharmaceut infant formula
price-to-earnings oper ep
risk assess reflect view
rel inexpens over-the-counter product larg
unaffect econom cycl chang govern
reimburs compani also strong
competit advantag largest maker store
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr stock trade
star recommend
recent chang buy
hold highlight section stock
report updat accordingli
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
hold keep
target line peer
ep estim ep
vs ahead view
consum healthcar
sale aid fx benefit rose
howev prescript pharmaceut sale
expect partli due
price eros suppli disrupt
new product scopolamin launch
believ re-launch
scopolamin along
anticip launch gener proair although
cautiou prescript
pharmaceut unit encourag
improv consum healthcar unit
america oper margin improv
bp unit
saw oper margin improv bp
share lower today
trade ep estim
peer attract valu
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview lead global health care supplier develop manufactur
distribut over-the-count over-the-counter prescript pharmaceut nutrit product activ
pharmaceut ingredi api consum product world largest manufactur
over-the-counter pharmaceut product privat label store brand market store brand product contain
activ ingredi advertis brand lower cost consum store brand
retail sell product store anoth chosen brand name
consum product compris broad line over-the-counter store brand product compar qualiti efficaci
advertis brand product cost retail store brand product significantli lower
compar nation advertis brand name product retail therefor price store
brand product compet nation brand product yet realiz greater profit margin store
major consum product categori includ analges cough/cold/allergy/sinu medic
gastrointestin smoke cessat item exampl store brand analges acetaminophen
activ ingredi brand tylenol consum product also includ broad rang household
product includ cosmet toiletri deterg bar soap sold carelin neca
gener busi focus develop manufactur sale gener prescript
pharmaceut primarili market manufactur oper base israel
spray liquid suspens solut well nasal spray oral liquid transderm product
compani also manufactur market brand prescript drug licens firm
pharmaceut medic diagnost product import israel exclus
agreement primarili chemagi busi manufactur complex chemic
activ pharmaceut ingredi api use world-wide gener drug industri certain
ingredi also use pharmaceut product api facil israel germani
china nutrit compris infant formula product infant toddler food oral electrolyt
solut product well vitamin miner dietari supplement product
compani sell product chain drug store wholesal distributor hospit system
group purchas organ well retail drug supermarket mass merchandis chain
also collabor agreement
cobrek pharmaceut
impact major develop gener busi augment juli acquisit
paddock laboratori million cash februari purchas rosemont
pharmaceut million expans veterinari product facilit
acquisit sergeant pet million septemb velcera million
april decemb acquir corpor billion subsequ
re-loc corpor headquart ireland believ lower corpor tax rate ireland
enabl compani save million tax annual march acquir omega pharma
nv billion omega develop over-the-count product annual sale billion
chairman board
global oper
senior director
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
e-estim na-not avail nm-not meaning nr-not rank ur-und review prior fiscal year end jun
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook pharmaceut
sub-industri next month neutral
although believ trump
administr push regulatori
chang forc drug price believ
third parti payer health insur
pharmaci benefit manag pbm along
public pressur media effect
pharmaceut firm announc
rais price drug
year histor drug price increas
account signific portion firm
tweet work new
system competit
drug industri drug price
come follow comment share
price drug firm declin markedli
volatil industri increas
price innov work group
releas draft execut order aim
tackl high drug price draft focus
reduc regul method increas
competit lower drug price strengthen
properti right scale back discount
given hospit serv lower incom
patient import note mani
individu serv work group
former pharmaceut execut like
cfra view put forward
separ believ top-lin pressur
patent expir mani top-sel drug
bottom anticip modest
organ sale increas low-singl digit
howev see modest benefit
foreign exchang follow
soften dollar late
also see expand sale new innov
drug therapi margin improv
accru cost restructur merger
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev repeal individu mandat
compon requir
peopl health insur pay fine
includ tax cut job act
pass decemb repeal
mandat effect januari
expect fewer insur patient
despit advers effect patent
expir pressur high drug price
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri number
new molecular entiti approv rebound
approv number
approv sinc
record approv follow robust
approv
approv
 pharmaceut index
increas versu rise
 composit index year date
april
declin composit index
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
view transit year tysabri sale
continu weak intern consum health care unit
improv america unit brand pharmaceut /jeffrey loo cfa
announc restat fy
transit period soon practic restat base
determin auditor ernst young
tysabri royalti stream record financi asset rather
intang asset also identifi defer tax asset adjust
result reduct goodwil off-set reduct defer
tax liabil separ provid preliminari sale
guid sale exclud tysabri rang /jeffrey
perrigo compani plc lower target
ep estim account
dilut sale tysabri royalti set ep sell
tysabri royalti royalti pharma cash potenti
mileston delay file auditor need time review
impair calcul relat tysabri deal past tysabri incom
stream guid sale includ tysabri revenu
api unit ep includ tysabri contribut
perrigo compani plc rais target price
in-lin peer forward ep estim
amid peer multipl contract price pressur lower ep
estim lower sale outlook former omega busi
said conduct strateg portfolio review includ multipl
sclerosi drug tysabri gener royalti revenu
expect finish review tysabri gener stabl predict
royalti stream anticip gradual declin next sever year
buy hold keep target
line peer ep estim ep vs
ahead view consum healthcar america sale rose
consum healthcar sale aid fx benefit
rose howev prescript pharmaceut sale
expect partli due price eros suppli disrupt new
product scopolamin launch believ
re-launch scopolamin along anticip launch
gener proair although cautiou prescript pharmaceut
unit encourag improv consum healthcar unit
america oper margin improv bp
unit saw oper margin improv bp share lower
today trade ep estim peer
attract valu view /jeffrey loo cfa
keep target line peer
ep estim near mid-point five-year rang
set ep vs ahead
estim forma sale modestli segment show posit
growth encourag result appear restructur
includ sale asset gener posit result expect new
ceo uwe roehrhoff evalu strateg plan provid flat modest
sale growth wide ep rang /jeffrey loo cfa
share significantli reschedul
earn releas slate today state need addit time
complet final incom tax review procedur relat reconcili
non-cash item new date given howev provid preliminari
sale line forecast state gener net sale
segment guidanc also state oper cash flow
compani guidanc base metric believ earn
line forecast /jeffrey loo cfa
et cfra keep hold opinion share compani plc
rais target peer
forward ep estim ep vs
ahead estim rais ep estim
consum healthcar improv oversea
pro-forma sale prescript sale rose oper
margin improv across three segment well encourag
result restructur includ sale certain asset
note highli competit market price pressur /jeffrey loo cfa
et cfra keep hold opinion share compani plc
keep target price in-lin
peer forward ep estim ep vs
ahead estim follow signific improv
intern consum healthcar unit pro forma sale rose
encourag improv oper continu portfolio
restructur divest under-perform asset includ announc sale
isra api unit howev still anticip volatil
intern unit rais ep estim /jeffrey
et cfra keep hold opinion share compani plc
keep target in-lin peer
ep estim lower ep
refil account recent sold tysabri royalti
financi asset rather intang asset file
soon practic guid sale ep
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
